Cargando…

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

The prevalence of multiple myeloma (MM) is increasing in Nordic countries and the rest of the western world. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all MM patients, but are underrepresented in randomized clinical trials. There is an urgent need for studies of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kari Lenita Falck, Turesson, Ingemar, Genell, Anna, Klausen, Tobias W., Knut-Bojanowska, Dorota, Redder, Louise, Sverrisdottir, Ingigerdur, Thorsen, Jonathan, Vangsted, Annette J., Blimark, Cecilie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230423/
https://www.ncbi.nlm.nih.gov/pubmed/36300775
http://dx.doi.org/10.3324/haematol.2021.280424
_version_ 1785051524201709568
author Moore, Kari Lenita Falck
Turesson, Ingemar
Genell, Anna
Klausen, Tobias W.
Knut-Bojanowska, Dorota
Redder, Louise
Sverrisdottir, Ingigerdur
Thorsen, Jonathan
Vangsted, Annette J.
Blimark, Cecilie H.
author_facet Moore, Kari Lenita Falck
Turesson, Ingemar
Genell, Anna
Klausen, Tobias W.
Knut-Bojanowska, Dorota
Redder, Louise
Sverrisdottir, Ingigerdur
Thorsen, Jonathan
Vangsted, Annette J.
Blimark, Cecilie H.
author_sort Moore, Kari Lenita Falck
collection PubMed
description The prevalence of multiple myeloma (MM) is increasing in Nordic countries and the rest of the western world. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all MM patients, but are underrepresented in randomized clinical trials. There is an urgent need for studies of the characteristics, treatment and outcome in this cohort. We present data from two nationwide population-based registries of all MM patients diagnosed in Denmark from January 1, 2005 until February 18, 2020, and in Sweden from January 1, 2008 until December 31, 2019, including treatment data for patients diagnosed until 2018 (Denmark) and 2019 (Sweden). In total 4,647 patients were ≥75 years at diagnosis, compared to 7,378 younger patients. Patients ≥75 years, accounting for approximately 40% of all MM patients, are a distinct cohort with more advanced disease at diagnosis, reflected by higher International Staging System (ISS) stage, and a higher proportion have renal failure and anemia. We found a more gradual introduction of modern medications in the older cohort than in the younger, despite simultaneous changes in guidelines. Compared to the cohorts in randomized controlled trials that guide the treatment of non-transplant eligible patients, we found a higher proportion of patients ≥75 years and presenting with ISS III in the real-world populations. Nevertheless, response rates and survival are increasing, indicating that modern treatment regimens are effective and well tolerated also in elderly MM patients in real-world populations.
format Online
Article
Text
id pubmed-10230423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-102304232023-06-01 Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden Moore, Kari Lenita Falck Turesson, Ingemar Genell, Anna Klausen, Tobias W. Knut-Bojanowska, Dorota Redder, Louise Sverrisdottir, Ingigerdur Thorsen, Jonathan Vangsted, Annette J. Blimark, Cecilie H. Haematologica Article - Plasma Cell Disorders The prevalence of multiple myeloma (MM) is increasing in Nordic countries and the rest of the western world. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all MM patients, but are underrepresented in randomized clinical trials. There is an urgent need for studies of the characteristics, treatment and outcome in this cohort. We present data from two nationwide population-based registries of all MM patients diagnosed in Denmark from January 1, 2005 until February 18, 2020, and in Sweden from January 1, 2008 until December 31, 2019, including treatment data for patients diagnosed until 2018 (Denmark) and 2019 (Sweden). In total 4,647 patients were ≥75 years at diagnosis, compared to 7,378 younger patients. Patients ≥75 years, accounting for approximately 40% of all MM patients, are a distinct cohort with more advanced disease at diagnosis, reflected by higher International Staging System (ISS) stage, and a higher proportion have renal failure and anemia. We found a more gradual introduction of modern medications in the older cohort than in the younger, despite simultaneous changes in guidelines. Compared to the cohorts in randomized controlled trials that guide the treatment of non-transplant eligible patients, we found a higher proportion of patients ≥75 years and presenting with ISS III in the real-world populations. Nevertheless, response rates and survival are increasing, indicating that modern treatment regimens are effective and well tolerated also in elderly MM patients in real-world populations. Fondazione Ferrata Storti 2022-10-27 /pmc/articles/PMC10230423/ /pubmed/36300775 http://dx.doi.org/10.3324/haematol.2021.280424 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article - Plasma Cell Disorders
Moore, Kari Lenita Falck
Turesson, Ingemar
Genell, Anna
Klausen, Tobias W.
Knut-Bojanowska, Dorota
Redder, Louise
Sverrisdottir, Ingigerdur
Thorsen, Jonathan
Vangsted, Annette J.
Blimark, Cecilie H.
Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title_full Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title_fullStr Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title_full_unstemmed Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title_short Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
title_sort improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in denmark and sweden
topic Article - Plasma Cell Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230423/
https://www.ncbi.nlm.nih.gov/pubmed/36300775
http://dx.doi.org/10.3324/haematol.2021.280424
work_keys_str_mv AT moorekarilenitafalck improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT turessoningemar improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT genellanna improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT klausentobiasw improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT knutbojanowskadorota improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT redderlouise improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT sverrisdottiringigerdur improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT thorsenjonathan improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT vangstedannettej improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden
AT blimarkcecilieh improvedsurvivalinmyelomapatientsanationwideregistrystudyof4647patients75yearstreatedindenmarkandsweden